Silibinin Is a Potent Antiviral Agent in Patients With Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy

Gastroenterology

Volumn 135, Issue 5, 2008, Pages 1561-1567

  Ferenci, Peter ^a   Scherzer, Thomas Matthias ^a   Kerschner, Heidrun ^a   Rutter, Karoline ^a   Beinhardt, Sandra ^a   Hofer, Harald ^a   Schöniger Hekele, Maximilian ^a   Holzmann, Heidemarie ^a   Steindl Munda, Petra ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN; SILIBININ; SILYMARIN; VIRUS RNA;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEADACHE; HEPATITIS C; HUMAN; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VIRUS LOAD;

EID: 55249084176     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2008.07.072     Document Type: Article

References (29)

1. Lee D.Y., and Liu Y. Molecular structure and stereochemistry of silybin A, silybin B, isosilybin A, and isosilybin B, isolated from Silybum marianum (milk thistle). J Nat Prod 66 (2003) 1171-1174
2. Pietrangelo A., Borella F., Casalgrandi G., et al. Antioxidant activity of silybin in vivo during long-term iron overload in rats. Gastroenterology 109 (1995) 1941-1949
3. Lucena M.I., Andrade R.J., de la Cruz J.P., et al. Effects of Silymarin MZ-80 on oxidative stress in patients with alcoholic cirrhosis. Results of a randomized, double-blind, placebo-controlled clinical study. Int J Clin Pharmacol Ther 40 (2002) 2-8
4. Mira L., Silva M., and Manso C.F. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem Pharmacol 48 (1994) 753-759
5. Boigk G., Stroedter L., Herbst H., et al. Silymarin retards collagen accumulation in early and advanced bilary fibrosis secondary to complete bile duct obliteration in rats. Hepatology 26 (1987) 643-649
6. Dehmlow C., Erhard J., and de Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of silibinin. Hepatology 23 (1996) 749-754
7. Ferenci P., Dragosics B., Dittrich H., et al. Randomized controlled trial of Silymarin treatment in patients with cirrhosis of the liver. J Hepatol 9 (1989) 105-113
8. Verma S., and Thuluvath P.J. Complementary and alternative medicine in hepatology: review of the evidence of efficacy. Clin Gastroenterol Hepatol 5 (2007) 408-416
9. Hruby K., Csomos G., Fuhrmann M., et al. Chemotherapy of Amanita phalloides poisoning with intravenous silibinin. Hum Toxicol 2 (1983) 138-195
10. Sonnenbichler J., and Zetl I. Biochemical effects of the flavonolignane silibinin on RNA, protein and DNA synthesis in rat livers. Prog Clin Biol Res 213 (1986) 319-331
11. Koike K., and Miyoshi H. Oxidative stress and hepatitis C viral infection. Hepatol Res 34 (2006) 65-73
12. Waris G., Turkson J., Hassanein T., et al. Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. J Virol 79 (2005) 1569-1580
13. Okuda M., Li K., Beard M.R., et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 122 (2002) 366-375
14. Janssen Y.M., Matalon S., and Mossman B.T. Differential induction of c-fos, c-jun, and apoptosis in lung epithelial cells exposed to ROS or RNS. Am J Physiol 273 (1997) 789-796
15. Di Bona D., Cippitelli M., Fionda C., et al. Oxidative stress inhibits IFN-α-induced antiviral gene expression by blocking the JAK-STAT pathway. J Hepatol 45 (2006) 271-279
16. Cesarone M., Belcaro G., Carratelli M., et al. A simple test to monitor oxidative stress. Int Angiol 18 (1999) 127-130
17. Polyak S.J., Morishima C., Shuhart M.C., et al. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-κB signaling, and HCV infection by standardized Silymarin. Gastroenterology 132 (2007) 1925-1936
18. Varghese L., Agarwal C., Tyagi A., et al. Silibinin efficacy against human hepatocellular carcinoma. Clin Cancer Res 11 (2005) 8441-8448
19. Tanamly M.D., Tadros F., Labeeb S., et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: study description and 12-month results. Dig Liver Dis 36 (2004) 752-759
20. Gabbay E., Zigmond E., Pappo O., et al. Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trial. World J Gastroenterol 13 (2007) 5317-5323
21. Zhang L., Zuo Z., and Lin G. Intestinal and hepatic glucuronidation of flavonoids. Mol Pharmaceutics 4 (2007) 833-845
22. Gordon A., Hobbs D.A., Bowden D.S., et al. Effects of Silybum marianum on serum hepatitis C virus RNA, alanine aminotransferase levels and well-being in patients with chronic hepatitis C. J Gastroenterol Hepatol 21 (2006) 275-280
23. Wen Z., Dumas T.E., Schrieber S.J., et al. Pharmacokinetics and metabolic profile of free, conjugated and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract. Drug Metab Dispos 36 (2008) 65-72
24. Schrieber S.J., Wen Z., Dumas T.E., et al. Silymarin pharmacokinetics (PK) is altered in patients with chronic hepatitis C (HCV) and nonalcoholic fatty liver disease (NAFLD) and correlates with caspase 3/7 activity. Hepatology 46 Suppl 1 (2007) A-392
25. Lee J., Wu C.C., Lee K.J., et al. Activation of anti-hepatitis C virus responses via Toll-like receptor 7. Proc Natl Acad Sci U S A 103 (2006) 1828-1833
26. Grandvaux N., Gaboriau F., Harris J., et al. Regulation of arginase II by interferon regulatory factor 3 and the involvement of polyamines in the antiviral response. FEBS J 272 (2005) 3120-3131
27. Platanias L.C. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol Ther 98 (2003) 129-142
28. Nahmias Y., Goldwasser J., Casali M., et al. Apolipoprotein B-dependent hepatitis c virus secretion is inhibited by the grapefruit flavonoid naringenin. Hepatology 47 (2008) 1437-1445
29. Sabile A., Perlemuter G., Bono F., et al. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology 30 (1999) 1064-1076